ÂÜÀòÂÒÂ×

Ying Zhang has extensive work experience in the field of scientific research and pharmaceuticals. They have held various roles in different companies.

From December 2022 (ongoing), Ying Zhang works as a Senior Principal Scientist at Janux Therapeutics.

From September 2016 to November 2022, Ying Zhang worked as a Senior Scientist at Ferring Pharmaceuticals.

In May 2016, Ying Zhang briefly worked as a Research Scientist, MetID at XenoBiotic Laboratories, Inc., a subsidiary of WuXi AppTec, Inc.

From December 2011 to December 2015, Ying Zhang worked as a Doctorant at Université de Genève, where they developed and optimized proteomic workflows for dendritic cell research, focusing on anti-viral responses.

From July 2007 to July 2011, Ying Zhang worked as a Senior Research Associate at Synta Pharmaceuticals, specializing in analytical method development, optimization, and validation.

In April 2007, Ying Zhang briefly worked as a Research Associate at Takeda San Diego, Inc.

From December 2004 to March 2007, Ying Zhang worked as a Senior Analytical Chemist/Supervisor at Silliker JR Laboratories Inc., where they conducted various analytical chemistry duties.

Overall, Ying Zhang's work experience showcases their expertise in scientific research, proteomic analysis, pharmaceuticals, and analytical chemistry.

Ying Zhang obtained a PhD in Pharmaceutical Science with a specialization in Mass Spectrometry based Proteomics from the University of Geneva, where they studied from 2011 to 2015. They also pursued further education by acquiring a Certificate in Intermediate PK/PD Modeling using Phoenix WinNonlin from Certara University in 2021-2022, and a Certificate in Advanced PK/PD Modeling using Phoenix WinNonlin from the same institution in 2022. Continuing their professional development, Zhang obtained a Certificate in Drug Discovery and Development from UC San Diego Extended Studies from 2019 to 2022. Prior to these achievements, Zhang completed an MSc degree in Chemistry at the University of Bristol from 2003 to 2005.